Prognostic value of novel biomarkers compared with detailed biochemical evaluation in patients with heart failure

Polskie Archiwum Medycyny Wewnetrznej

Volumn 125, Issue 6, 2015, Pages 434-442

  Rywik, Tomasz M ^a   Janas, Jadwiga ^a   Klisiewicz, Anna ^a   Leszek, Przemysław ^a   Sobieszczańska Małek, Małgorzata ^a   Kurjata, Paweł ^a   Rozentryt, Piotr ^b   Korewicki, Jerzy ^a   Jerzak Wodzyńska, Grazyna ^a   Zieliński, Tomasz ^a  

^a INSTITUTE OF CARDIOLOGY   (Poland)

^b MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Biochemical tests; Biomarkers; Heart failure; Prognosis

Indexed keywords

ACETYLSALICYLIC ACID; ALANINE AMINOTRANSFERASE; ALDOSTERONE ANTAGONIST; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BILIRUBIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CATECHOLAMINE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GELATINASE B; GROWTH HORMONE; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HIGH SENSITIVITY C REACTIVE PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MYELOPEROXIDASE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; SODIUM; SOMATOMEDIN; SOMATOMEDIN C; TROPONIN I; UNCLASSIFIED DRUG; URIC ACID;

ADULT; ARTICLE; ATRIAL FIBRILLATION; BIOCHEMICAL ANALYSIS; CELLULAR DISTRIBUTION; CEREBROVASCULAR DISEASE; CORONARY ARTERY DISEASE; DEATH; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART TRANSPLANTATION; HEMOGLOBIN BLOOD LEVEL; HOSPITALIZATION; HUMAN; HYPERTENSION; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; KIDNEY FAILURE; LABORATORY TEST; LEUKOCYTE COUNT; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; PATIENT CARE; POPULATION; PREDICTIVE VALUE; PROGNOSIS; PROSPECTIVE STUDY; THYROID DISEASE; AGED; BLOOD; MIDDLE AGED;

ADULT; AGED; BIOMARKERS; FEMALE; GLOMERULAR FILTRATION RATE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; SODIUM; URIC ACID;

EID: 84936850301     PISSN: 00323772     EISSN: 18979483     Source Type: Journal    
DOI: 10.20452/pamw.2884     Document Type: Article

References (51)

1. Rywik TM, Koziarek J, Piotrowski W, et al. Trends in heart failure mortality in Poland between 1980 and 2010. Pol Arch Med Wewn. 2013; 123: 664-671.
2. Ky B, French B, Levy WC, et al. Multiple biomarkers for risk prediction in chronic heart failure. Circ Heart Fail. 2012; 5: 183-190.
3. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013; 62: 1495-1539.
4. Braunwald E. Biomarkers in heart failure. N Engl J Med. 2008; 358: 2148-2159.
5. van Kimmenade RR, Januzzi JL, Jr. Emerging biomarkers in heart failure. Clin Chem. 2012; 58: 127-138.
6. Gheorghiade M, Abraham WT, Albert NM, et al. Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: An analysis from the OPTIMIZE-HF registry. Eur Heart J. 2007; 28: 980-988.
7. Charach G, Rabinovich A, Ori A, et al. Low levels of low-density lipoprotein cholesterol: A negative predictor of survival in elderly patients with advanced heart failure. Cardiology. 2014; 127: 45-50.
8. Kim H, Yoon HJ, Park HS, et al. Potentials of cystatin C and uric acid for predicting prognosis of heart failure. Congest Heart Fail. 2013; 19: 123-129.
9. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012; 33: 1787-1847.
10. Pencina MJ, D'Agostino RB S, D'Agostino RB Jr, et al. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008; 27: 157-172.
11. Lippi G, Mattiuzzi C. The biomarker paradigm: between diagnostic efficiency and clinical efficacy. Pol Arch Med Wewn. 2015; 125: 282-288.
12. Wang TJ, Gona P, Larson MG, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med. 2006; 355: 2631-2639.
13. Velagaleti RS, Gona P, Larson MG, et al. Multimarker approach for the prediction of heart failure incidence in the community. Circulation. 2010; 122: 1700-1706.
14. Melander O, Newton-Cheh C, Almgren P, et al. Novel and conventional biomarkers for prediction of incident cardiovascular events in the community. JAMA. 2009; 302: 49-57.
15. Kalogeropoulos AP, Georgiopoulou VV, Butler J. Clinical adoption of prognostic biomarkers: The case for heart failure. Prog Cardiovasc Dis. 2012; 55: 3-13.
16. Volpe M, Francia P, Tocci G, et al. Prediction of long-term survival in chronic heart failure by multiple biomarker assessment: A 15-year prospective follow-up study. Clin Cardiol. 2010; 33: 700-707.
17. von Haehling S, Filippatos GS, Papassotiriou J, et al. Mid-regional proadrenomedullin as a novel predictor of mortality in patients with chronic heart failure. Eur J Heart Fail. 2010; 12: 484-491.
18. Neuhold S, Huelsmann M, Strunk G, et al. Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease. J Am Coll Cardiol. 2008; 52: 266-272.
19. Cohn JN. Detecting the patient at risk of heart failure. J Am Coll Cardiol. 2010; 55: 2138-2139.
20. Yang DH. The risk model for prediction of survival in heart failure. Korean Circ J. 2012; 42: 657-658.
21. Ky B, French B, McCloskey K, et al. High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure. Circ Heart Fail. 2011; 4: 180-187.
22. Masson S, Latini R, Carbonieri E, et al. The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure: data from the GISSI-heart failure (GISSI-HF) trial. Eur J Heart Fail. 2010; 12: 338-347.
23. Dunlay SM, Gerber Y, Weston SA, et al. Prognostic value of biomarkers in heart failure: Application of novel methods in the community. Circ Heart Fail. 2009; 2: 393-400.
24. Pascual-Figal DA, Manzano-Fernandez S, Boronat M, et al. Soluble ST2, high-sensitivity troponin T- And N-terminal pro-B-type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure. Eur J Heart Fail. 2011; 13: 718-725.
25. Bayes-Genis A, de Antonio M, Vila J, et al. Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3. J Am Coll Cardiol. 2014; 63: 158-166.
26. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2012; 14: 803-869.
27. Jankowska EA, Ponikowska B, Majda J, et al. Hyperuricaemia predicts poor outcome in patients with mild to moderate chronic heart failure. Int J Cardiol. 2007; 115: 151-155.
28. Biegus J, Zymlinski R, Sokolski M, et al. Liver function tests in patients with acute heart failure. Pol Arch Med Wewn. 2012; 122: 471-479.
29. Rusinaru D, Tribouilloy C, Berry C, et al. Relationship of serum sodium concentration to mortality in a wide spectrum of heart failure patients with preserved and with reduced ejection fraction: An individual patient data meta-analysis(dagger): Meta-Analysis Global Group in Chronic heart failure (MAGGIC). Eur J Heart Fail. 2012; 14: 1139-1146.
30. Vaduganathan M, Ambrosy AP, Greene SJ, et al. Predictive value of low relative lymphocyte count in patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. Circ Heart Fail. 2012; 5: 750-758.
31. Charach G, George J, Roth A, et al. Baseline low-density lipoprotein cholesterol levels and outcome in patients with heart failure. Am J Cardiol. 2010; 105: 100-104.
32. Ketchum ES, Levy WC. Establishing prognosis in heart failure: A multimarker approach. Prog Cardiovasc Dis. 2011; 54: 86-96.
33. Sobczak S, Wojtczak-Soska K, Ciurus T, et al. Single sST2 protein measurement predicts adverse outcomes at 1-year follow-up in patients with chronic heart failure. Pol Arch Med Wewn. 2014; 124: 452-458.
34. Wu AH. Biological and analytical variation of clinical biomarker testing: implications for biomarker-guided therapy. Curr Heart Fail Rep. 2013; 10: 434-440.
35. Rocchiccioli JP, McMurray JJ, Dominiczak AF. Biomarkers in heart failure: A clinical review. Heart Fail Rev. 2010; 15: 251-273.
36. Allen LA, Felker GM, Mehra MR, et al. Validation and potential mechanisms of red cell distribution width as a prognostic marker in heart failure. J Card Fail. 2010; 16: 230-238.
37. Felker GM, Allen LA, Pocock SJ, et al. Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank. J Am Coll Cardiol. 2007; 50: 40-47.
38. Michalik C, Matusik P, Nowak J, et al. Heart failure, comorbidities, and polypharmacy among elderly nursing home residents. Pol Arch Med Wewn. 2013; 123: 170-175.
39. Rywik TM, Kolodziej P, Targonski R, et al. Characteristics of the heart failure population in Poland: ZOPAN, a multicentre national programme. Kardiol Pol. 2011; 69: 24-31.
40. Damman K, Valente MA, Voors AA, et al. Renal impairment, worsening renal function, and outcome in patients with heart failure: An updated metaanalysis. Eur Heart J. 2014; 35: 455-469.
41. Dries DL, Exner DV, Domanski MJ, et al. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol. 2000; 35: 681-689.
42. Loffler AI, Cappola TP, Fang J, et al. Effect of renal function on prognosis in chronic heart failure. Am J Cardiol. 2015; 115: 62-68.
43. Smith GL, Lichtman JH, Bracken MB, et al. Renal impairment and outcomes in heart failure: Systematic review and meta-analysis. J Am Coll Cardiol. 2006; 47: 1987-1996.
44. Bettari L, Fiuzat M, Shaw LK, et al. Hyponatremia and long-term outcomes in chronic heart failure-an observational study from the Duke Databank for Cardiovascular Diseases. J Card Fail. 2012; 18: 74-81.
45. Kaplon-Cieslicka A, Ozieranski K, Balsam P, et al. Clinical characteristics and 1-year outcome of hyponatremic patients hospitalized for heart failure. Pol Arch Med Wewn. 2015; 125: 120-131.
46. Allen LA, Felker GM, Pocock S, et al. Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Eur J Heart Fail. 2009; 11: 170-177.
47. Auer J. What does the liver tell us about the failing heart? Eur Heart J. 2013; 34: 711-714.
48. Rauchhaus M, Clark AL, Doehner W, et al. The relationship between cholesterol and survival in patients with chronic heart failure. J Am Coll Cardiol. 2003; 42: 1933-1940.
49. Huehnergarth KV, Mozaffarian D, Sullivan MD, et al. Usefulness of relative lymphocyte count as an independent predictor of death/urgent transplant in heart failure. Am J Cardiol. 2005; 95: 1492-1495.
50. Anker SD, Doehner W, Rauchhaus M, et al. Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation. 2003; 107: 1991-1997.
51. Duan X, Ling F. Is uric acid itself a player or a bystander in the pathophysiology of chronic heart failure? Med Hypotheses. 2008; 70: 578-581.